ARS Pharmaceuticals (SPRY) Insider Dadoo Buys 30,000 Shares
Rajeev Dadoo recently bought 30,000 shares of ARS Pharmaceuticals, joining other insiders in significant purchases.
Reviewed by automated data checks against the source filing. How we make and check alerts
Rajeev Dadoo bought 30,000 shares of ARS Pharmaceuticals, Inc. ($SPRY) on June 24, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $SPRY is down 24.7% after 1 week, down 43.6% after 1 month and down 61.9% to date (from the $10.54 close on Jun 24, 2026).
SPRY
ARS Pharmaceuticals, Inc.
Key Points
- On June 24, 2026, Rajeev Dadoo bought 30,000 shares of ARS Pharmaceuticals at $8.54 each, reflecting a growing interest in the company.
- ARS Pharmaceuticals has seen multiple insiders, including Phillip Schneider and Pratik Shah, also buy 30,000 shares each on the same day.
- Analysts maintain a strong buy rating for ARS Pharmaceuticals, with a mean price target of $22.50 based on four opinions.
Get $SPRY trade alerts by text
We text you when insiders, Congress or big funds trade $SPRY. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated ARS Pharmaceuticals, Inc. alert may contain errors. Disclosures
Insider Buying and Selling at ARS Pharmaceuticals, Inc.
Rajeev Dadoo purchased 30,000 shares of ARS Pharmaceuticals, Inc. (NasdaqGM: SPRY) on June 24, 2026, at a price of $8.54 each. This trade adds to a series of insider purchases at the company, highlighting confidence in its future prospects.
A Wave of Insider Purchases
Dadoo's acquisition is part of a broader trend, as several insiders bought shares on the same day. Phillip Schneider, Pratik Shah, Saqib Islam, Brent Saunders, Laura Shawver, and Peter Thompson each purchased 30,000 shares at $8.54. These transactions suggest a strong collective belief in the company's direction.
Analysts Set New Price Targets
On June 25, 2026, Leerink Partners maintained its Outperform rating for ARS Pharmaceuticals, adjusting the price target to $24.00 from a previous $25.00. The following month, on August 13, 2026, they reaffirmed an Outperform rating but lowered the target to $18.00. Analysts currently have a consensus recommendation of strong buy, with a mean price target of $22.50 across four analyst opinions.
How ARS Pharmaceuticals, Inc. Stock Has Traded
Currently trading at $8.54, ARS Pharmaceuticals is positioned near its 52-week high of $13.15. The stock has shown resilience, particularly as it has risen from a low of $4.07 over the past year. This recent insider buying comes as the company develops innovative treatments for severe allergic reactions, including its needle-free delivery system for epinephrine.
What ARS Pharmaceuticals, Inc. Does
ARS Pharmaceuticals, Inc., based in San Diego, California, focuses on developing treatments for severe allergic reactions. Its flagship product, neffy, offers a needle-free way to deliver epinephrine during emergencies. The company has been active in expanding its market presence since its founding in 2015.
What’s Next for ARS Pharmaceuticals
Investors should keep an eye on upcoming earnings, with the next report scheduled for November 10, 2026. The recent insider trades reflect a strong commitment to the company's future, while the 13F filings provide a retrospective view of ownership. As always, these filings may not represent the current positions of the insiders.
Related Filing Alerts
Source: Rajeev Dadoo's Form 4 filing on $SPRY (Jun 24, 2026). Find the original filing: SPRY Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts